Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

Press/Media: Press / Media

PeriodJun 24 2018 → Jun 26 2018

Media coverage

44

Media coverage

  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date6/26/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People ...
    Media name/outletADVFN Deutschland
    CountryGermany
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletSpoke.com
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletTickerTech.com
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKSWO
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKNDO KNDU
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKHQ Right Now
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletNBC12 Online
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKSLA
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletVenture Beat Profiles
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWTOC TV
    CountryGeorgia
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKuam News 8
    CountryGuam
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKAUZ
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outlet14 WFIE
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWMBF
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKait 8
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKLTV 7
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWLBT
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletNews 9
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletFOX 14 TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWSFA
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletLive 5 WCSC
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWBOC TV 16
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWFMJ 21 - TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWTVM
    CountryGeorgia
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKFMB-TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outlet19 Action News
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKOTV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWDAM-TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWTOL-TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKTRE
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKWES NewsWest 9
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKTVN
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKOAM TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletKFVS12
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletChannel 8 Eyewitness News
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletFox 19
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWave 3
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWMCTV.com
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWECT TV-6
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWLOX
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletHawaii News Now
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo
  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletWIS-TV
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo